Immuno-oncology https://www.bioworld.com/rss en-us CSPC’s SYS-6051 cleared for clinic in China for solid tumors http://www.bioworld.com/articles/730429 Thu, 16 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730429-cspcs-sys-6051-cleared-for-clinic-in-china-for-solid-tumors 3D rendering of an antibody-drug conjugate China’s NMPA accepts Mabwell’s IND application for 6MW5311 http://www.bioworld.com/articles/730428 Thu, 16 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730428-chinas-nmpa-accepts-mabwells-ind-application-for-6mw5311 Microscopic image of acute myeloid leukemia (AML) cells. Acute myeloid leukemia cells. Credit: Cincinnati Children's Glyconex’s GNX-1021 cleared for clinic in Japan for GI cancers http://www.bioworld.com/articles/730373 Wed, 15 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730373-glyconexs-gnx-1021-cleared-for-clinic-in-japan-for-gi-cancers Floating antibody drug conjugates KDTV-001: a trivalent HPV vaccine with broad and durable antitumor immunity http://www.bioworld.com/articles/730372 Wed, 15 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730372-kdtv-001-a-trivalent-hpv-vaccine-with-broad-and-durable-antitumor-immunity Senescent tumor-derived nanovesicles restore antitumor immunity http://www.bioworld.com/articles/730351 Tue, 14 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730351-senescent-tumor-derived-nanovesicles-restore-antitumor-immunity Illustration of cancer tumor Kazia Therapeutics licenses SETDB1 platform from QIMR Berghofer http://www.bioworld.com/articles/730347 Tue, 14 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730347-kazia-therapeutics-licenses-setdb1-platform-from-qimr-berghofer Concept of business partnership Solve Therapeutics patents new anti-5T4 ADCs http://www.bioworld.com/articles/730337 Mon, 13 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730337-solve-therapeutics-patents-new-anti-5t4-adcs Second CRL for Replimune’s RP-1 for melanoma http://www.bioworld.com/articles/730363 Fri, 10 Apr 2026 17:01:36 -0400 https://www.bioworld.com/articles/730363-second-crl-for-replimunes-rp-1-for-melanoma Photo of magnifying glass inspecting moles on person's back Selective CBL-B inhibitor with improved safety profile disclosed http://www.bioworld.com/articles/730243 Thu, 09 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730243-selective-cbl-b-inhibitor-with-improved-safety-profile-disclosed Cancer cell in the cross-hairs Next-generation anti-CD30 ADC outperforms brentuximab vedotin http://www.bioworld.com/articles/730169 Tue, 07 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730169-next-generation-anti-cd30-adc-outperforms-brentuximab-vedotin Illustration of antibodies targeting cancer cell Canwell gains IND clearance for ADC CAN-016 http://www.bioworld.com/articles/730166 Tue, 07 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730166-canwell-gains-ind-clearance-for-adc-can-016 Illustration of magnifying glass and antibodies Akari Therapeutics partners with Wuxi XDC on ADC payload http://www.bioworld.com/articles/730165 Tue, 07 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730165-akari-therapeutics-partners-with-wuxi-xdc-on-adc-payload 3D rendering of antibody drug conjugated with cytotoxic payload Janux nominates development candidate under BMS collaboration http://www.bioworld.com/articles/730099 Thu, 02 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730099-janux-nominates-development-candidate-under-bms-collaboration Illustration of tumor Ernexa eyes clinic with ERNA-101 for ovarian cancer http://www.bioworld.com/articles/730095 Thu, 02 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730095-ernexa-eyes-clinic-with-erna-101-for-ovarian-cancer Fosun gains clinical trial approval in China for FXB-0871 http://www.bioworld.com/articles/730093 Thu, 02 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730093-fosun-gains-clinical-trial-approval-in-china-for-fxb-0871 3D illustration of tumor Tyligand Bioscience divulges new dual-drug antibody-drug conjugates http://www.bioworld.com/articles/730048 Tue, 31 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730048-tyligand-bioscience-divulges-new-dual-drug-antibody-drug-conjugates Antitumoral antibodies cross the BBB and alter brain signaling http://www.bioworld.com/articles/730035 Tue, 31 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730035-antitumoral-antibodies-cross-the-bbb-and-alter-brain-signaling Antibodies and synaptic neuron CGT-19 as an approach to expand CAR T-cell therapy accessibility http://www.bioworld.com/articles/730015 Mon, 30 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730015-cgt-19-as-an-approach-to-expand-car-t-cell-therapy-accessibility CD19 binding CAR T targeting CD44E splicing variant shows potential for HCC treatment http://www.bioworld.com/articles/730000 Fri, 27 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730000-car-t-targeting-cd44e-splicing-variant-shows-potential-for-hcc-treatment Illustration of tumor in the liver More than two to tango: multispecifics at ESMO TAT http://www.bioworld.com/articles/729995 Fri, 27 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729995-more-than-two-to-tango-multispecifics-at-esmo-tat Antibodies artwork The Scripps Research Institute identifies new DNA topoisomerase inhibitors http://www.bioworld.com/articles/729942 Thu, 26 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729942-the-scripps-research-institute-identifies-new-dna-topoisomerase-inhibitors Bolt Biotherapeutics discloses new STING agonist immunoconjugates http://www.bioworld.com/articles/729941 Thu, 26 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729941-bolt-biotherapeutics-discloses-new-sting-agonist-immunoconjugates Oncolytic virotherapy boosts antitumor immunity in cSCC 90%) with surgical excision when detected early, it carries a significant risk of local invasion and metastasis if left untreated.]]> http://www.bioworld.com/articles/729876 Wed, 25 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729876-oncolytic-virotherapy-boosts-antitumor-immunity-in-cscc Overt Bio advances OVT-101 toward clinic http://www.bioworld.com/articles/729861 Tue, 24 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729861-overt-bio-advances-ovt-101-toward-clinic Ovarian cancer illustration Glyconex and Nippon Kayaku collaborate on GNX201-ADC http://www.bioworld.com/articles/729857 Tue, 24 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729857-glyconex-and-nippon-kayaku-collaborate-on-gnx201-adc Kelun-Biotech’s SKB-103 cleared to enter clinic in China http://www.bioworld.com/articles/729855 Tue, 24 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729855-kelun-biotechs-skb-103-cleared-to-enter-clinic-in-china 3D illustration demonstrating antibody-drug conjugate. DLL3-targeted T-cell therapy shows efficacy in MTC models http://www.bioworld.com/articles/729793 Mon, 23 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729793-dll3-targeted-t-cell-therapy-shows-efficacy-in-mtc-models Illustration of cancer cells and immunotherapy treatment First-in-class anti-TRPV6 antibody for advanced prostate cancer http://www.bioworld.com/articles/729773 Fri, 20 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729773-first-in-class-anti-trpv6-antibody-for-advanced-prostate-cancer 3D illustration showing presence of tumor inside prostate gland ENPP1 inhibitors show promise for cancer immunotherapy http://www.bioworld.com/articles/729723 Thu, 19 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729723-enpp1-inhibitors-show-promise-for-cancer-immunotherapy Concept art for oncology research Nanobody CAR construct targeting CLL-1 shows preclinical activity against AML http://www.bioworld.com/articles/729694 Wed, 18 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729694-nanobody-car-construct-targeting-cll-1-shows-preclinical-activity-against-aml Nanoparticle illustration